CT26 tumor-bearing allografted mice were subsequently established to evaluate the efficacy of AaLS/LOX/CAT in vivo and the local treatments of tumor-bearing mice with appropriate AaLS/LOX/CAT (10 μM) amounts effectively consumed lactate to modulate the TME and produced adequate amounts of H2O2, which was high enough to suppress tumor growth, but not too high to result in any serious side effects. The gene discussed is LOX; the disease is neoplasm.